Karyopharm Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Good day, everyone, and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Steve [Berce], I'm an equity research associate here at H.C. Wainwright, and it is my pleasure to welcome Richard Paulson, President and Chief Executive Officer of Karyopharm Therapeutics; and Reshma Rangwala, Chief Medical Officer.
So I'll turn it over to Richard Paulson.
Thanks, Steven. Thanks, H.C. Wainright for having us here today. We're pleased to be joining you and showing some more about the Karyopharm story. Just a little housekeeping before we begin. As you know, various comments we make today will be forward-looking statements, so please refer to our most recent 10-Q.
So Karyopharm is an innovation and patient-focused company, which is passionately driven in the submission to positively impact patient's lives and defeat cancer. And we're an organization and that is a leader in the science of the selective inhibition nuclear
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |